This site is intended for healthcare professionals
  • Home
  • /
  • Drugs
  • /
  • V VARIOUS
  • /
  • V03
  • /
  • V03A
  • /
  • V03AC
  • /
  • V03AC01
  • /
  • Desferrioxamine Mesilate 500 mg and 2 g Powder for...
Drug information

Desferrioxamine

POM
Read time: 21 mins
Last updated: 06 May 2020
Published: 24 Jul 2020

4.1 Therapeutic indications

Iron overload - acute iron poisoning; primary and secondary haemochromatosis including thalassaemia and transfusional haemosiderosis; in patients in whom concomitant disorders (e.g. severe anaemia, hypoproteinaemia, renal or cardiac failure) preclude phlebotomy; and for the diagnosis of iron storage disease and sideroblastic anaemia, auto-immune haemolytic anaemia and other chronic anaemias.

Aluminium overload - in patients on maintenance dialysis for end stage renal failure where preventative measures (e.g. reverse osmosis) have failed and with proven aluminium-related bone disease and/or anaemia, dialysis encephalopathy; and for diagnosis of aluminium overload.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).